Target 2035 – an update on private sector contributions

^b ProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain
E-mail: aantolin@idibell.cat

^c A Division of Janssen-Cilag S.A., Janssen Research and Development, Toledo, Spain
E-mail: jbartolo@its.jnj.com, JLlaveri@ITS.JNJ.com

^d Research and Development, Bayer AG, Pharmaceuticals, 42103 Wuppertal, Germany
E-mail: hartmut.beck@bayer.com, jan.dreher@bayer.com, alexander.hillisch@bayer.com

^e Center for Medicines Discovery, Old Road Campus, University of Oxford, Roosevelt Drive, Headington, Oxford, UK
E-mail: alex.bullock@cmd.ox.ac.uk, jon.elkins@cmd.ox.ac.uk

^f Merck KGaA, Darmstadt, Germany
E-mail: ulrich.betz@merckgroup.com, Sven.Lindemann@merckgroup.com

^g Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
E-mail: jark.boettcher@boehringer-ingelheim.com

^h Structural Genomics Consortium, University of North Carolina at Chapel Hill, USA
E-mail: peter.brown@unc.edu

ⁱ Boehringer Ingelheim International, Binger Str. 173, D-55216 Ingelheim, Germany
E-mail: menorca.chaturvedi@boehringer-ingelheim.com, markus.koester@boehringer-ingelheim.com, oliver.kraemer@boehringer-ingelheim.com

^j Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK
E-mail: Alisa.crisp@icr.ac.uk

^k Foghorn Therapeutics, 500 Technology Square, Suite 700, Cambridge, MA 02139, USA
E-mail: DDaniels@foghorntx.com

^l Structural Genomics Consortium, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden
E-mail: kristina.edfeldt@ki.se, michael.sundstrom@ki.se

^m Nuvisan Innovation Campus Berlin GmbH, Müllerstraße 178, Berlin, Germany
E-mail: egner.target2035@web.de, anke.mueller-fahrnow@nuvisan.com

ⁿ Discovery Chemistry, Merck & Co., Inc., Boston, Massachusetts 02115, USA
E-mail: christian_fischer@merck.com

^o Research & Early Development, Novo Nordisk A/S, Måløv, Denmark
E-mail: tgle@novonordisk.com, lrli@novonordisk.com

^p Janssen Research and Development LLC, San Diego, California, USA
E-mail: SGoldbe1@its.jnj.com, ssharm505@ITS.JNJ.com, BShirema@its.jnj.com, JVenable@its.jnj.com

^q Medicinal Chemistry, Global R&D, Merck Healthcare KGaA, Frankfurter Straße 250, Darmstadt, Germany
E-mail: ingo.hartung@merckgroup.com

^r Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
E-mail: evert.homan@ki.se, maurice.grube@scilifelab.se

^s Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt 60438, Germany
E-mail: knapp@pharmchem.uni-frankfurt.de, tredup@pharmchem.uni-frankfurt.de

^t Structural Genomics Consortium, BMLS, Goethe University Frankfurt, Frankfurt 60438, Germany
E-mail: susanne.mueller-knapp@bmls.de

^u Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, D-88397 Biberach an der Riss, Germany
E-mail: uta.lessel@boehringer-ingelheim.com

^v Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
E-mail: hisanori.matsui@takeda.com

^w Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, D-88397 Biberach an der Riss, Germany
E-mail: florian.montel@boehringer-ingelheim.com

^x Discovery Network Group, Pfizer Medicine Design, Cambridge, MA 02139, USA
E-mail: Dafydd.Owen@pfizer.com

^y Global Research Externalization, Takeda California, Inc., 9625 Towne Center Drive, San Diego, CA 92121, USA
E-mail: kumar.saikatendu@takeda.com

^z Janssen Research & Development, Janssen Pharmaceutica N. V, Beerse, Belgium
E-mail: WSANDERS@its.jnj.com

^aa Research and Development, Bayer AG, Pharmaceuticals, 13353 Berlin, Germany
E-mail: cora.scholten@bayer.com

^ab Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario M5S 1A8, Canada

^ac School of Pharmacy, University College London, London, UK
E-mail: mattoddchem@gmail.com

^ad Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
E-mail: tim.willson@unc.edu

^ae Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Abstract

Target 2035, an international federation of biomedical scientists from the public and private sectors, is leveraging ‘open’ principles to develop a pharmacological tool for every human protein. These tools are important reagents for scientists studying human health and disease and will facilitate the development of new medicines. It is therefore not surprising that pharmaceutical companies are joining Target 2035, contributing both knowledge and reagents to study novel proteins. Here, we present a brief progress update on Target 2035 and highlight some of industry's contributions.

RSC Medicinal Chemistry